GlassScriptPhysician profile
Kelli Mills
NPI 1235622390
$5,015.62
in general payments reported to CMS, 2019-2025
19 companies · $1,813 in 2025
The $1,813 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $259 · 2022: $351 · 2023: $1,153 · 2024: $1,440 · 2025: $1,813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,405.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $883.94 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $793.71 | 2022-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Vanda Pharmaceuticals INC. | $566.31 | 2024-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $540.25 | 2021-2025 | Spravato |
| Alkermes, INC. | $422.08 | 2021-2025 | Lybalvi, Aristada |
| E.R. Squibb & Sons, L.L.C. | $246.89 | 2025 | Cobenfy |
| Lundbeck LLC | $243.13 | 2021-2025 | Rexulti |
| Axsome Therapeutics, INC. | $223.40 | 2022-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $218.97 | 2022-2024 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $200.98 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $127.42 | 2021-2025 | Trintellix |
| Almatica Pharma LLC | $99.95 | 2024-2025 | Loreev Xr |
| Teva Pharmaceuticals USA, INC. | $92.63 | 2025 | Austedo Xr, Uzedy |
| Biogen, INC. | $86.90 | 2025 | Zurzuvae |
| Supernus Pharmaceuticals, INC. | $79.45 | 2022-2025 | Qelbree, Qelbree |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $72.50 | 2025 | Sublocade |
| Idorsia Pharmaceuticals US INC | $57.22 | 2022-2024 | Quviviq |
| Neurocrine Biosciences, INC. | $44.26 | 2022-2025 | Ingrezza |
| Avanir Pharmaceuticals, INC. | $15.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelli Mills listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.